Whitehawk Therapeutics (WHWK) reported a second-quarter 2026 net loss of $16.6 million, compared with a net loss of $52.6 million in the year-earlier period. The clinical-stage oncology company ended June 30, 2026, with $190.0 million in cash, cash equivalents and short-term investments, which it said is anticipated to fund operations into the second half of 2028.
Whitehawk said Phase 1 trials for HWK-007 and HWK-016 continue to enroll, while a Phase 1 trial for HWK-206 is on track to begin in the third quarter of 2026. The company also reported an $87.5 million private placement financing announced in May 2026 and recent agreements with Hangzhou DAC and Biocytogen.
- Research and development expenses were $12.9 million for Q2 2026, compared with $48.8 million for Q2 2025.
- Cash, cash equivalents and short-term investments were $190.0 million as of June 30, 2026.
- HWK-007 and HWK-016 remain in ongoing Phase 1 recruitment, with initial results expected in the first half of 2027.
- HWK-206 is planned to enter a Phase 1 study in small-cell lung cancer and neuroendocrine tumors in Q3 2026.
- Whitehawk entered an option agreement with Hangzhou DAC for CPT113 access and a Biocytogen collaboration for bispecific antibody ADC development.
$WHWK Insider Trading Activity
$WHWK insiders have traded $WHWK stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.
Here’s a breakdown of recent trading of $WHWK stock by insiders over the last 6 months:
- DAVID JAMES LENNON (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 6 sales selling 306,885 shares for an estimated $1,058,892.
- SCOTT M. GIACOBELLO (CHIEF FINANCIAL OFFICER) has made 0 purchases and 3 sales selling 221,194 shares for an estimated $890,613.
- BRYAN BALL (See remarks) has made 0 purchases and 5 sales selling 177,279 shares for an estimated $635,054.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$WHWK Hedge Fund Activity
We have seen 38 institutional investors add shares of $WHWK stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. added 550,441 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,899,021
- MILLENNIUM MANAGEMENT LLC added 309,674 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,068,375
- WOODLINE PARTNERS LP added 281,497 shares (+inf%) to their portfolio in Q1 2026, for an estimated $971,164
- VERDAD ADVISERS, LP added 115,484 shares (+inf%) to their portfolio in Q1 2026, for an estimated $398,419
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 93,382 shares (+84.8%) to their portfolio in Q1 2026, for an estimated $322,167
- JANE STREET GROUP, LLC added 81,179 shares (+116.1%) to their portfolio in Q1 2026, for an estimated $280,067
- MARSHALL WACE, LLP removed 67,959 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $234,458
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
